Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT

Multiple Cancer Types

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patients response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Germ Cell (Pediatrics), Pediatrics
II
Esbenshade, Adam
NCT04684368
COGACNS2021

Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Embryonal Tumors

Neuroblastoma (Pediatrics)

This phase IV trial studies how well standard chemotherapy works in treating young patients with medulloblastoma or other central nervous system embryonal tumors. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Neuroblastoma (Pediatrics)
IV
Esbenshade, Adam
NCT02875314
VICCPED1751

Evaluation of Immunologic Response following COVID-19 Vaccination in Children, Adolescents, and Young Adults with Cancer

Pediatrics

This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the bodys immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the bodys natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and number of vaccine doses or boosts (extra vaccine shots) may strengthen or diminish the bodys protective immune response. This study may help researchers learn more about how the bodys immune system responds to the COVID-19 vaccine when the vaccination is given during or after cancer treatment.
Pediatrics
N/A
Esbenshade, Adam
NCT05228275
COGACCL21C2

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents with Cancer

Multiple Cancer Types

This randomized clinical phase III trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with cancer. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.
Pediatric Leukemia, Pediatrics
N/A
Esbenshade, Adam
NCT03223753
COGALTE1631

REACH (Research, Education, Advocacy, Clinical Care and Health) for Survivorship Program: Long Term Effects for Survivors of Cancer

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED0710

Infectious Disease Outcomes in Pediatric Oncology Patients

Multiple Cancer Types

Miscellaneous, Pediatrics
N/A
Esbenshade, Adam
VICCPED14127

Developing Evidence-Based Criteria for Initiating Treatment for Neurofibromatosis Type 1 Associated Optic Pathway Glioma

Multiple Cancer Types

Neuro-Oncology, Pediatrics
N/A
Esbenshade, Adam
VICCPED17108

Expanded Access to Trametinib for a child with Plexiform Neurofibroma in NF1

Pediatrics

Pediatrics
N/A
Esbenshade, Adam
VICCPED2251

Clinical Trials Search CTA Inline Referral Form

To learn more about any of our clinical
trials, call 615-936-8422.